-
公开(公告)号：US20170340594A1
公开(公告)日：2017-11-30
申请号：US15607125
申请日：2017-05-26
发明人： Yogesh Bapurao PAWAR , Kailas KHOMANE , Saurabh SRIVASTAVA , Bijay Kumar PADHI , Rajeev Singh RAGHUVANSHI
CPC分类号： A61K31/203 , A61K9/0002 , A61K9/146 , A61K9/2022 , A61K9/4808 , A61K9/5026 , A61K9/5042 , A61K9/5047 , A61K47/12 , A61K47/32
摘要： The present application relates to pharmaceutical compositions comprising retinoic acid or its derivatives such as isotretinoin and processes for preparing thereof. It also provides methods for treating acne by administering such pharmaceutical composition to a patient in need thereof.
-
公开(公告)号：US20220241298A1
公开(公告)日：2022-08-04
申请号：US17471858
申请日：2021-09-10
IPC分类号： A61K31/635 , A61K47/14 , A61K47/44 , A61K9/00 , A61K9/08 , A61K47/10 , A61K9/10 , A61K31/415 , A61K47/26
摘要： The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or its pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted-State Simulated Gastric Fluid (FaSSGF) at pH 2.0, temperature of 37° C.±0.5° C. and under stirring at a speed of 50 rpm at least for 60 minutes. It also relates to the process of preparing and method of using said composition of celecoxib.
-
公开(公告)号：US20200085775A1
公开(公告)日：2020-03-19
申请号：US16690789
申请日：2019-11-21
发明人： Yogesh Bapurao PAWAR , Kailas KHOMANE , Saurabh SRIVASTAVA , Bijay Kumar PADHI , Rajeev Singh RAGHUVANSHI
摘要： The present application relates to pharmaceutical compositions comprising retinoic acid or its derivatives such as isotretinoin and processes for preparing thereof. It also provides methods for treating acne by administering such pharmaceutical composition to a patient in need thereof.
-
公开(公告)号：US20180008619A1
公开(公告)日：2018-01-11
申请号：US15712415
申请日：2017-09-22
CPC分类号： A61K31/635 , A61K9/0053 , A61K9/0095 , A61K9/08 , A61K9/10 , A61K31/415 , A61K47/10 , A61K47/14 , A61K47/26 , A61K47/44
摘要： The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or its pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted-State Simulated Gastric Fluid (FaSSGF) at pH 2.0, temperature of 37° C.±0.5° C. and under stirring at a speed of 50 rpm at least for 60 minutes. It also relates to the process of preparing and method of using said composition of celecoxib.
-
公开(公告)号：US20160296537A1
公开(公告)日：2016-10-13
申请号：US15093673
申请日：2016-04-07
CPC分类号： A61K31/65 , A61K9/0053 , A61K9/2072 , A61K9/2077 , A61K9/2866 , A61K9/2886
摘要： The present application relates to a method of orally administering once daily tablet of minocycline to a subject in need thereof, wherein said tablet is substantially free of lactose. The present application also relates to processes for preparing said once daily tablet of minocycline that provides reduced stock keeping units with improved inventory by supplying multiple doses of minocycline in single tablet.
摘要翻译： 本申请涉及一种口服每日一粒米诺环素片剂到有需要的受试者的方法，其中所述片剂基本上不含乳糖。 本申请还涉及制备所述每日一次的米诺环素片剂的方法，其通过在单个片剂中提供多剂量的米诺环素来提供具有改善的库存的减少的库存单位。
-
公开(公告)号：US20210353649A1
公开(公告)日：2021-11-18
申请号：US17388133
申请日：2021-07-29
摘要： The present application relates to a method of orally administering once daily tablet of minocycline to a subject in need thereof, wherein said tablet is substantially free of lactose. The present application also relates to processes for preparing said once daily tablet of minocycline that provides reduced stock keeping units with improved inventory by supplying multiple doses of minocycline in single tablet.
-
公开(公告)号：US20190224219A1
公开(公告)日：2019-07-25
申请号：US16369981
申请日：2019-03-29
IPC分类号： A61K31/635 , A61K31/415 , A61K9/10 , A61K9/00 , A61K47/10 , A61K47/14 , A61K47/26 , A61K9/08 , A61K47/44
摘要： The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or its pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted-State Simulated Gastric Fluid (FaSSGF) at pH 2.0, temperature of 37° C.±0.5° C. and under stirring at a speed of 50 rpm at least for 60 minutes. It also relates to the process of preparing and method of using said composition of celecoxib.
-
公开(公告)号：US20230131030A1
公开(公告)日：2023-04-27
申请号：US17844715
申请日：2022-06-20
发明人： Swati KULKARNI , Bijay Kumar PADHI , Shanvas ALIKUNJU , Rajeev Singh RAGHUVANSHI , Srinivas Ramchandra SIDGIDDI , Anirudh GAUTAM
IPC分类号： A61K31/165 , A61P17/02 , A61P17/06 , A61P17/10 , A61K31/65 , A61P17/04 , A61P17/00 , A61P29/00 , A61K9/00
摘要： The present application relates to a method of treating an inflammatory skin condition by administering a pharmaceutical composition comprising a reduced dose of minocycline to a subject in need thereof, wherein said administration provides an effective plasma or interstitial fluid concentration of minocycline for treating the inflammatory skin condition.
-
公开(公告)号：US20210121420A1
公开(公告)日：2021-04-29
申请号：US17132825
申请日：2020-12-23
发明人： Swati KULKARNI , Bijay Kumar PADHI , Shanvas ALIKUNJU , Rajeev Singh RAGHUVANSHI , Srinivas Ramchandra SIDGIDDI , Anirudh GAUTAM
IPC分类号： A61K31/165 , A61P17/02 , A61P17/06 , A61P17/10 , A61K31/65 , A61P17/04 , A61P17/00 , A61P29/00 , A61K9/00
摘要： The present application relates to a method of treating an inflammatory skin condition by administering a pharmaceutical composition comprising a reduced dose of minocycline to a subject in need thereof, wherein said administration provides an effective plasma or interstitial fluid concentration of minocycline for treating the inflammatory skin condition.
-
公开(公告)号：US20200222345A1
公开(公告)日：2020-07-16
申请号：US16827622
申请日：2020-03-23
发明人： Swati KULKARNI , Bijay Kumar PADHI , Shanvas ALIKUNJU , Rajeev Singh RAGHUVANSHI , Srinivas Ramchandra SIDGIDDI , Anirudh GAUTAM
IPC分类号： A61K31/165 , A61P17/02 , A61P17/06 , A61P17/10 , A61K31/65 , A61P17/04 , A61P17/00 , A61P29/00 , A61K9/00
摘要： The present application relates to a method of treating an inflammatory skin condition by administering a pharmaceutical composition comprising a reduced dose of minocycline to a subject in need thereof, wherein said administration provides an effective plasma or interstitial fluid concentration of minocycline for treating the inflammatory skin condition.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.017 秒)
